Long-term Experience With Abatacept SC in Routine Clinical Practice
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the retention rate of Abatacept SC over 24 months in
routine clinical practice, in rheumatoid arthritis patients, in each country involved in the
study. The purpose of the UK substudy is to explore whether integrating self-assessment into
routine care could maintain tight control (of inflammation/disease activity) and at
potentially lower cost resulting in improved health outcomes and cost-effectiveness.